Diagnostic value of sialyl-Tn immunocytochemistry in breast cancer presenting with pathological nipple discharge.


Journal

Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310

Informations de publication

Date de publication:
03 2021
Historique:
received: 29 10 2020
revised: 06 02 2021
accepted: 07 02 2021
pubmed: 20 2 2021
medline: 17 7 2021
entrez: 19 2 2021
Statut: ppublish

Résumé

Mucin-associated sialyl-Tn (sTn) antigen is overexpressed and related with adverse outcome in breast cancer (BC). The role of sTn in BC has not been well defined in pathological nipple discharge (PND) cytology. The authors examined sTn immunocytochemistry (ICC) in PND to determine whether it could be a biomarker of malignancy or aggressive disease. PND was subjected to immunocytochemical staining for sTn antigen expression and thinprep cytology test (TCT) for enhancing the sensitivity and specificity. The examination data was compared with histological findings of subsequent biopsy specimens. Logistic regression analysis was used to determine which factors were most associated with malignant breast lesions. PND specimens were collected including 120 cases of intraductal papilloma, 24 cases of hyperplasia, 45 cases of ductal carcinoma in situ (DCIS), and 48 cases of invasive ductal carcinoma (IDC). STn ICC differentiated BC from benign intraductal lesions with a low sensitivity of 41.9% and a high specificity of 95.8%, but increased in combination with TCT to 64.5% and 100%, respectively. A high degree of concordance was observed between the results of sTn expression in cell smears and histological specimens. Moreover, the sTn expression was strongly associated with HER2-positive IDC (p = 0.039). Multivariate logistic analysis showed that positive sTn expression (OR: 14.241, 95%CI: 2.574, 78.794, p = 0.010) and accompanying mass (OR: 3.307, 95%CI: 1.073, 10.188, p = 0.037) were statistically significant independent risk factors for malignant PND. Mucin-associated sTn expression in PND cytology appears to be a reliable diagnostic marker for BC patients with the chief complaint of malignant nipple discharge and indicates a more aggressive behavior in IDC.

Sections du résumé

BACKGROUND
Mucin-associated sialyl-Tn (sTn) antigen is overexpressed and related with adverse outcome in breast cancer (BC). The role of sTn in BC has not been well defined in pathological nipple discharge (PND) cytology. The authors examined sTn immunocytochemistry (ICC) in PND to determine whether it could be a biomarker of malignancy or aggressive disease.
METHODS
PND was subjected to immunocytochemical staining for sTn antigen expression and thinprep cytology test (TCT) for enhancing the sensitivity and specificity. The examination data was compared with histological findings of subsequent biopsy specimens. Logistic regression analysis was used to determine which factors were most associated with malignant breast lesions.
RESULTS
PND specimens were collected including 120 cases of intraductal papilloma, 24 cases of hyperplasia, 45 cases of ductal carcinoma in situ (DCIS), and 48 cases of invasive ductal carcinoma (IDC). STn ICC differentiated BC from benign intraductal lesions with a low sensitivity of 41.9% and a high specificity of 95.8%, but increased in combination with TCT to 64.5% and 100%, respectively. A high degree of concordance was observed between the results of sTn expression in cell smears and histological specimens. Moreover, the sTn expression was strongly associated with HER2-positive IDC (p = 0.039). Multivariate logistic analysis showed that positive sTn expression (OR: 14.241, 95%CI: 2.574, 78.794, p = 0.010) and accompanying mass (OR: 3.307, 95%CI: 1.073, 10.188, p = 0.037) were statistically significant independent risk factors for malignant PND.
CONCLUSIONS
Mucin-associated sTn expression in PND cytology appears to be a reliable diagnostic marker for BC patients with the chief complaint of malignant nipple discharge and indicates a more aggressive behavior in IDC.

Identifiants

pubmed: 33605547
doi: 10.1002/cam4.3793
pmc: PMC7940227
doi:

Substances chimiques

Antigens, Tumor-Associated, Carbohydrate 0
Biomarkers, Tumor 0
sialosyl-Tn antigen 0
ERBB2 protein, human EC 2.7.10.1
Receptor, ErbB-2 EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1783-1790

Informations de copyright

© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Références

Cell Mol Biol (Noisy-le-grand). 2017 Feb 28;63(2):92-95
pubmed: 28364788
Cancer. 1997 Dec 15;80(12):2240-9
pubmed: 9404700
Cancer Detect Prev. 2004;28(1):27-31
pubmed: 15041074
Cancer Manag Res. 2020 Feb 11;12:1017-1027
pubmed: 32104083
Cancer Res. 1996 May 1;56(9):2229-32
pubmed: 8616877
Cancer Res. 1993 Apr 1;53(7):1706-8
pubmed: 8453646
Clin Breast Cancer. 2010 Jun;10(3):238-45
pubmed: 20497923
Breast J. 2006 Sep-Oct;12(5 Suppl 2):S210-7
pubmed: 16959004
Surgeon. 2010 Oct;8(5):252-8
pubmed: 20709281
Biomolecules. 2012 Oct 11;2(4):435-66
pubmed: 24970145
Cancer Res. 2008 Mar 15;68(6):1636-46
pubmed: 18339842
Biosci Rep. 2020 Jun 26;40(6):
pubmed: 32452513
PLoS One. 2018 Jul 27;13(7):e0201314
pubmed: 30052649
Onkologie. 2010;33(6):307-12
pubmed: 20523094
Eur J Surg Oncol. 2009 Jun;35(6):573-7
pubmed: 18986790
Int J Clin Exp Pathol. 2015 Sep 01;8(9):11549-54
pubmed: 26617889
Int J Mol Sci. 2016 Feb 24;17(3):275
pubmed: 26927062
Oncology. 2001;61(4):299-305
pubmed: 11721177
PLoS One. 2015 May 07;10(5):e0125994
pubmed: 25951175
Pathol Res Pract. 1996 Dec;192(12):1181-6
pubmed: 9182286
BMC Cancer. 2017 May 2;17(1):300
pubmed: 28464874
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6868-71
pubmed: 16203776
J Hematol Oncol. 2019 Dec 21;12(1):140
pubmed: 31864424
Adv Exp Med Biol. 2001;491:369-402
pubmed: 14533809

Auteurs

Feng Xu (F)

Department of Breast Surgery, Beijing Chao-Yang Hospital, Beijing, China.

Yue Gao (Y)

Department of General Surgery, Beijing Huairou Hospital, Beijing, China.

Xiaoli Diao (X)

Department of Pathology, Beijing Chao-Yang Hospital, Beijing, China.

Jie Li (J)

Department of Breast Surgery, Beijing Chao-Yang Hospital, Beijing, China.

Hongchuan Jiang (H)

Department of Breast Surgery, Beijing Chao-Yang Hospital, Beijing, China.

Hongying Zhao (H)

Department of Pathology, Beijing Chao-Yang Hospital, Beijing, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH